Arrowhead Pharmaceuticals

This study tested an experimental drug called ARO-ANG3 in 18 people with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol and early heart disease. Participants received two doses of the drug and were monitored for 36 wee…

This study tested an experimental drug called ARC-520 in adults with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could further reduce hepatitis B surface antigen levels in the blood. The trial was stopped early…

This study tested an experimental drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if ARC-520 could lower hepatitis B surface antigen levels more than placebo. The trial was terminated early, so res…

This study tested an experimental drug called ARO-ENaC in healthy volunteers and people with cystic fibrosis. The goal was to see if it is safe and helps lung function. The trial was stopped early, so results are limited.

This early-stage study tested an experimental drug called ARC-521 in healthy volunteers and people with chronic hepatitis B. The goal was to check safety and how the body processes the drug. The study was terminated early, so results are limited. It involved 47 participants and w…

This study tested a new drug called ARC-520, given with the standard medicine entecavir, to see if it could lower hepatitis B virus levels in people with chronic infection. The trial included 58 adults with different types of chronic hepatitis B. The study was stopped early, so r…

This study tested an experimental drug called ARC-520 in people with chronic hepatitis B. Some participants received ARC-520 alone, while others got it with standard treatments like entecavir or tenofovir. The goal was to see if the drug could lower hepatitis B surface antigen le…

This early-stage study tested a new drug called ARC-AAT in healthy volunteers and people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can damage the lungs and liver. The main goal was to check the drug's safety and how it affects AAT protein levels in the …

This study tested an experimental drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could safely lower a key virus marker (HBsAg) in the blood. Only 12 people who had shown some ini…

This study tested an inhaled drug called ARO-MUC5AC in healthy people and those with asthma or COPD. The goal was to see if it was safe and could improve lung function by reducing mucus. The study was terminated early, so results are limited.

This study tested an experimental drug called ARC-520, given alongside standard hepatitis B medications (entecavir or tenofovir), in people with chronic hepatitis B. The goal was to see if it could lower the amount of hepatitis B surface antigen in the blood. Only 4 people took p…